Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840826 · ClinicalTrials.gov registry record · NA
Reducing Hospital Readmissions in Patients With Depressive Symptoms
A NA study, sponsored by Boston Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 709
- Enrollment target
NCT01840826: Completed NA study, sponsored by Boston Medical Center.
NCT01840826 is a NA study that has completed, run by Boston Medical Center. The registered enrollment target is 709 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01840826, a NA study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 709 participants
- Enrollment target
Study Summary
Project Re-Engineered Discharge (Project RED) has previously demonstrated that patients who received the RED were 30% less likely than patients receiving usual care to access inpatient or emergency services within 30 days of discharge. In this project, the investigators add a new dimension to RED by integrating screening, referral and treatment for depression into the original RED intervention and determining if this enhanced intervention increases the effectiveness of RED in preventing readmissions and controlling costs in the 180 days after discharge for patients with signs of depression.
Primary Outcome
The primary hypothesis is to test whether the RED intervention plus the collaborative-care approach for depression (RED-D) will reduce the all-cause 30 and 90 day hospital readmission rates for patients who screen positive for depressive symptoms
Interventions
- OTHER RED-D Care Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 709 participants |
| Start Date | 2013-02 |
| Est. Completion | 2018-02 |
| Phase | NA |
What the finished NCT01840826 record still lists
NCT01840826 is an interventional study that assigns participants to a tested intervention. The registered 709 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which RED-D Care Management is the first listed.
NCT01840826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01840826 about?
NCT01840826 is a clinical study titled "Reducing Hospital Readmissions in Patients With Depressive Symptoms". Project Re-Engineered Discharge (Project RED) has previously demonstrated that patients who received the RED were 30% less likely than patients receiving usual care to access inpatient or emergency services within 30 days of discharge. In this project, the investigators add a new dimension to RED by...
What is the current status of trial NCT01840826?
This trial is currently completed. It is a NA study. The enrollment target is 709 participants. The study started on 2013-02. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01840826?
The interventions under investigation include: RED-D Care Management (OTHER).
Who is sponsoring clinical trial NCT01840826?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01840826's enrollment target sits among peer trials
709 148th of 2000 higher than 1,853 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia